TipRanks
BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
US Market
BBOT
BridgeBio Oncology Therapeutics
RESEARCH TOOLSreports
Want to see BBOT full AI Analyst Report?

BridgeBio Oncology Therapeutics (BBOT) Stock News & Sentiment

78 Followers
Analyst Maintains Buy Rating on BridgeBio Oncology Therapeutics, Reaffirming Unchanged $23 Price Target Ahead of Key 2026 KRAS Data Catalysts
Premium
Ratings
Analyst Maintains Buy Rating on BridgeBio Oncology Therapeutics, Reaffirming Unchanged $23 Price Target Ahead of Key 2026 KRAS Data Catalysts
2M ago
BBOT
BridgeBio Oncology Therapeutics: Buy Rating Reiterated as BBO‑10203 Value Catalysts Highlighted; Price Target Maintained at $23
Premium
Ratings
BridgeBio Oncology Therapeutics: Buy Rating Reiterated as BBO‑10203 Value Catalysts Highlighted; Price Target Maintained at $23
3M ago
BBOT
Analyst Initiates Buy on BridgeBio Oncology, Sees Significant Upside With $27 Price Target Amid Promising KRAS and PI3Kα Precision Oncology Pipeline
Premium
Ratings
Analyst Initiates Buy on BridgeBio Oncology, Sees Significant Upside With $27 Price Target Amid Promising KRAS and PI3Kα Precision Oncology Pipeline
3M ago
BBOT
BridgeBio Oncology Holders Elect Directors, Ratify Auditor
Premium
Company Announcements
BridgeBio Oncology Holders Elect Directors, Ratify Auditor
3M ago
8K
BBOT
John Newman Reiterates Buy on BridgeBio Oncology Therapeutics, Sets $23 Price Target on Differentiated KRAS G12C Profile
Premium
Ratings
John Newman Reiterates Buy on BridgeBio Oncology Therapeutics, Sets $23 Price Target on Differentiated KRAS G12C Profile
4M ago
BBOT
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
Premium
Company Announcements
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
5M ago
BBOT
Analyst Reiterates Buy on BridgeBio Oncology Therapeutics with Unchanged $29 12-Month Price Target Amid Promising Pan-KRAS Pipeline
Premium
Ratings
Analyst Reiterates Buy on BridgeBio Oncology Therapeutics with Unchanged $29 12-Month Price Target Amid Promising Pan-KRAS Pipeline
5M ago
BBOT
More BBOT News >

BBOT News on the Web

BridgeBio Oncology Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
Insider Monkey
Neutral
BridgeBio Oncology Therapeutics Inc at Citi Biopharma Back to School Summit Transcript
GuruFocus News
Neutral
BridgeBio Pharma files $500M mixed securities shelf
TipRanks News
Bullish
Enavate Sciences GP, LLC Reduces Zenas BioPharma Inc (ZBIO) Stake
GuruFocus News
Neutral
BridgeBio Oncology Therapeutics (BBOT) Receives a New Rating from Wedbush
TipRanks News
Bullish
BridgeBio Oncology Therapeutics (BBOT) Q2 Loss Highlights Challenges Amid Promising KRAS Data ...
GuruFocus News
Neutral
BridgeBio Oncology Therapeutics: Buy Rating Reiterated as BBO‑10203 Value Catalysts Highlighted; Price Target Maintained at $23
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average3.5 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BBOT’s Media Buzz Sentiment?
Currently, no data Available
What is BBOT’s weekly average amount of articles?
In an average week, 3.5 articles about BBOT are published.
    What is BBOT’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    RHHBYRoche Holding
    BAYRYBayer
    SNYSanofi
    CICigna
    TFXTeleflex
    Showing the stocks with the most bullish news sentiment over the past week